229 related articles for article (PubMed ID: 10993655)
1. Trafficking of 'immune' CD4(+)/CD8(+)T-lymphocytes into the RENCA tumour microcirculation in vivo in mice.
Ali SA; Rees RC; Anderson DQ; Reed MW; Goepel JR; Brown NJ
Br J Cancer; 2000 Oct; 83(8):1061-8. PubMed ID: 10993655
[TBL] [Abstract][Full Text] [Related]
2. Neutralization of interleukin-2 retards the growth of mouse renal cancer.
Fukuhara H; Matsumoto A; Kitamura T; Takeuchi T
BJU Int; 2006 Jun; 97(6):1314-21. PubMed ID: 16686731
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-2 blocks the antitumour activity caused by depletion of CD25 cells in a murine renal adenocarcinoma model.
Takeuchi T; Konno-Takahashi N; Kasuya Y; Ogushi T; Nishimatsu H; Kitamura T
BJU Int; 2004 Jul; 94(1):171-6. PubMed ID: 15217455
[TBL] [Abstract][Full Text] [Related]
5. Trafficking of activated lymphocytes into the RENCA tumour microcirculation in vivo in mice.
Brown NJ; Ali S; Reed MW; Wiltrout R; Rees RC
Br J Cancer; 1997; 76(12):1572-8. PubMed ID: 9413944
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity.
Saffran DC; Horton HM; Yankauckas MA; Anderson D; Barnhart KM; Abai AM; Hobart P; Manthorpe M; Norman JA; Parker SE
Cancer Gene Ther; 1998; 5(5):321-30. PubMed ID: 9824052
[TBL] [Abstract][Full Text] [Related]
7. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
Bristol JA; Schlom J; Abrams SI
Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumour activity of heat-shock protein 60-recognizing CD4+ T cells against syngeneic murine renal cell carcinoma.
Eto M; Harada M; Tatsugami K; Harano M; Koga H; Matsuzaki G; Naito S
BJU Int; 2005 Feb; 95(3):421-4. PubMed ID: 15679807
[TBL] [Abstract][Full Text] [Related]
9. Mode-of-action, efficacy, and safety of a homologous multi-epitope vaccine in a murine model for adjuvant treatment of renal cell carcinoma.
Doehn C; Esser N; Pauels HG; Kiessig ST; Stelljes M; Grossmann A; Jocham D; Drevs J
Eur Urol; 2009 Jul; 56(1):123-31. PubMed ID: 18550267
[TBL] [Abstract][Full Text] [Related]
10. Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer.
Wysocki PJ; Kazimierczak U; Suchorska W; Kotlarski M; Malicki J; Mackiewicz A
Cancer Gene Ther; 2010 Jul; 17(7):465-75. PubMed ID: 20168352
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of cancer vaccine therapy using cells transduced with the interleukin-12 gene combined with systemic interleukin-18 administration.
Hara I; Nagai H; Miyake H; Yamanaka K; Hara S; Micallef MJ; Kurimoto M; Gohji K; Arakawa S; Ichihashi M; Kamidono S
Cancer Gene Ther; 2000 Jan; 7(1):83-90. PubMed ID: 10678360
[TBL] [Abstract][Full Text] [Related]
12. Regional oral tolerance in transgenic 2C mice.
Margenthaler JA; Flye MW
Surgery; 2005 Aug; 138(2):141-9. PubMed ID: 16153420
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity.
Mendiratta SK; Quezada A; Matar M; Wang J; Hebel HL; Long S; Nordstrom JL; Pericle F
Gene Ther; 1999 May; 6(5):833-9. PubMed ID: 10505108
[TBL] [Abstract][Full Text] [Related]
14. Th2-like response and antitumor effect of anti-interleukin-4 mAb in mice bearing renal cell carcinoma.
Takeuchi T; Ueki T; Sasaki Y; Kajiwara T; Li B; Moriyama N; Kawabe K
Cancer Immunol Immunother; 1997 Jan; 43(6):375-81. PubMed ID: 9067410
[TBL] [Abstract][Full Text] [Related]
15. IL-4 deficiency does not impair the ability of dendritic cells to initiate CD4+ and CD8+ T cell responses in vivo.
Roberts JM; Yang J; Ronchese F
Int Immunol; 2004 Oct; 16(10):1451-8. PubMed ID: 15326095
[TBL] [Abstract][Full Text] [Related]
16. Partial degradation of T-cell signal transduction molecules by contaminating granulocytes during protein extraction of splenic T cells from tumor-bearing mice.
Franco JL; Ghosh P; Wiltrout RH; Carter CR; Zea AH; Momozaki N; Ochoa AC; Longo DL; Sayers TJ; Komschlies KL
Cancer Res; 1995 Sep; 55(17):3840-6. PubMed ID: 7641202
[TBL] [Abstract][Full Text] [Related]
17. The immunologic function of 1B2+ double negative (CD4-CD8-) T cells in the 2C transgenic mouse.
Margenthaler JA; Flye MW
J Surg Res; 2005 Jun; 126(2):160-6. PubMed ID: 15919414
[TBL] [Abstract][Full Text] [Related]
18. In vivo growth of transitional and renal cell carcinoma cell lines can be suppressed by the adenovirus-mediated expression of a soluble form of vascular endothelial growth factor receptor.
Ichikura H; Eto M; Ueno H; Harada M; Takayama K; Tokuda N; Tatsugami K; Naito S
Oncol Rep; 2006 May; 15(5):1333-7. PubMed ID: 16596207
[TBL] [Abstract][Full Text] [Related]
19. Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.
Suchorska WM; Dams-Kozlowska H; Kazimierczak U; Wysocki PJ; Mackiewicz A
Expert Opin Biol Ther; 2011 Dec; 11(12):1555-67. PubMed ID: 21995459
[TBL] [Abstract][Full Text] [Related]
20. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
VanOosten RL; Griffith TS
Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
